Novel Multi-Substituted Imidazolines with Potential Antimicrobial and Anti-inflammatory Application


Executive Summary


NF-kB is a transcription factor that regulates a large number of genes and biochemical pathways, including those involved in immune, inflammatory, and anti-apoptotic responses. Many areas of drug discovery are focused on developing reagents that regulate NF-kB. Imidazolines are potent inhibitors of NF-kB, and are currently being used to treat a wide variety of medical conditions, including asthma, arthritis, fungal infections and hypertension. Imidazolines exhibit other properties which make them potentially useful in enhancing the activity of chemotherapy agents.


Description of Technology


This technology consists of a new class of multi-substituted 4-acid or 4-alkyl ester imidazoline compounds that exhibit anti-microbial, anti-sepsis and anti-inflammatory activity. In addition, they potentially inhibit resistance to chemotherapy reagents. This invention describes the use and an improved method for synthesis and production of these unique imidazoline compounds.


Key Benefits

  • More potent inhibition of NF-KB: Will potentially lead to improved efficacy over other imidazolines and new applications. 
  • Improved method for synthesis: Will provide the ability to produce purer, more active material.




These compounds can potentially be used in the treatment of a wide variety of medical conditions including septic shock, inflammatory disorders such as arthritis and asthma, specific bacterial infections, and as a chemopotentiator in cancer treatments.


Patent Status


Issued patent number US 7858808




Jetze Tepe, Satyamaheshwar Peddibhotla


Tech ID




Alternative contact due to temporary leave:


Nina (Isi) Davis, Technology Marketing Manager, email:, phone (direct): (517)884-1829. 


Patent Information:

For Information, Contact:

Anne Disante
Associate Director
Michigan State University